Drug Type Dual payload Antibody drug conjugate (Dual payload ADC) |
Synonyms Dual-payload anti-NPTXR ADCs using third-generation 4+4 linker–payload architecture (MMAF + exatecan), YB 811, YB811 |
Target |
Action inhibitors |
Mechanism NPTXR inhibitors(neuronal pentraxin receptor inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H65N5O8 |
InChIKeyMFRNYXJJRJQHNW-DEMKXPNLSA-N |
CAS Registry745017-94-1 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | Switzerland | 01 Dec 2025 |






